AU2018311974B2 - Mavacamten for use in the treatment of hypertrophic cardiomyopathy - Google Patents

Mavacamten for use in the treatment of hypertrophic cardiomyopathy Download PDF

Info

Publication number
AU2018311974B2
AU2018311974B2 AU2018311974A AU2018311974A AU2018311974B2 AU 2018311974 B2 AU2018311974 B2 AU 2018311974B2 AU 2018311974 A AU2018311974 A AU 2018311974A AU 2018311974 A AU2018311974 A AU 2018311974A AU 2018311974 B2 AU2018311974 B2 AU 2018311974B2
Authority
AU
Australia
Prior art keywords
compound
subject
dose
lvef
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018311974A
Other languages
English (en)
Other versions
AU2018311974A1 (en
Inventor
Timothy Carlson
Marc EVANCHIK
Eric Green
Joseph Lambing
June H. LEE
Marc J. SEMIGRAN
David Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of AU2018311974A1 publication Critical patent/AU2018311974A1/en
Application granted granted Critical
Publication of AU2018311974B2 publication Critical patent/AU2018311974B2/en
Priority to AU2024203872A priority Critical patent/AU2024203872A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
AU2018311974A 2017-08-04 2018-08-03 Mavacamten for use in the treatment of hypertrophic cardiomyopathy Active AU2018311974B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203872A AU2024203872A1 (en) 2017-08-04 2024-06-07 Treatment of HCM with pyrimidinedione compounds

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US62/541,591 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US62/584,537 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US62/639,922 2018-03-07
US201862671585P 2018-05-15 2018-05-15
US62/671,585 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203872A Division AU2024203872A1 (en) 2017-08-04 2024-06-07 Treatment of HCM with pyrimidinedione compounds

Publications (2)

Publication Number Publication Date
AU2018311974A1 AU2018311974A1 (en) 2020-02-06
AU2018311974B2 true AU2018311974B2 (en) 2024-03-07

Family

ID=63350605

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018311974A Active AU2018311974B2 (en) 2017-08-04 2018-08-03 Mavacamten for use in the treatment of hypertrophic cardiomyopathy
AU2024203872A Pending AU2024203872A1 (en) 2017-08-04 2024-06-07 Treatment of HCM with pyrimidinedione compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203872A Pending AU2024203872A1 (en) 2017-08-04 2024-06-07 Treatment of HCM with pyrimidinedione compounds

Country Status (28)

Country Link
US (6) US20200054636A1 (https=)
EP (2) EP3661514B1 (https=)
JP (3) JP2020529996A (https=)
KR (2) KR20200035973A (https=)
CN (2) CN111182901A (https=)
AU (2) AU2018311974B2 (https=)
CA (1) CA3071948A1 (https=)
DK (1) DK3661514T3 (https=)
ES (1) ES3055679T3 (https=)
FI (1) FI3661514T3 (https=)
HR (1) HRP20251598T1 (https=)
HU (1) HUE073047T2 (https=)
IL (2) IL322175A (https=)
LT (1) LT3661514T (https=)
MA (1) MA49760B1 (https=)
MX (3) MX2020001406A (https=)
MY (1) MY208231A (https=)
PL (1) PL3661514T3 (https=)
PT (1) PT3661514T (https=)
RS (1) RS67534B1 (https=)
RU (1) RU2020109345A (https=)
SG (2) SG10202112960QA (https=)
SI (1) SI3661514T1 (https=)
SM (1) SMT202500413T1 (https=)
TW (1) TWI907332B (https=)
UA (1) UA130213C2 (https=)
UY (1) UY37834A (https=)
WO (1) WO2019028360A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
EP4054588A4 (en) * 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
HUE069154T2 (hu) * 2020-01-28 2025-02-28 Assia Chem Ind Ltd A mavakamten szilárd állapotú formái és eljárás elõállításukra
MX2023002024A (es) * 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
US20240082248A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PT4370116T (pt) * 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
US20240389972A1 (en) * 2021-09-24 2024-11-28 Koninklijke Philips N.V. METHODS AND SYSTEMS FOR GENERATING LIKELIHOOD OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス， インコーポレイテッド １，４－ジヒドロキナゾリノン化合物およびその使用
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160030428A1 (en) * 2013-06-21 2016-02-04 MyoKardia, Inc. Pyrimidinedione compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160030428A1 (en) * 2013-06-21 2016-02-04 MyoKardia, Inc. Pyrimidinedione compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Business Press Release, "MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients," July 11, 2016. (Year: 2016) *
Dearani et al. "Treating obstructive hypertrophic cardiomyopathy—what’s best, what’s next?" The Journal of Thoracic and Cardiovascular Surgery 2016 Volume 152, Number 4, 988-990 (Year: 2016) *
JOSHUA A. STERN ET AL: PLOS ONE, vol. 11, no. 12, 14 December 2016 (2016-12-14), pages e0168407, XP055514347, DOI: 10.1371/journal.pone.0168407 *
NCT02842242 Clinical Trials July 22, 2016 (Year: 2016) *
Zhang et al. "Cytochrome P450 reaction-phenotyping: an industrial perspective," Expert Opin. Drug Metab. Toxicol. (2007) 3(5):667-687. (Year: 2007) *

Also Published As

Publication number Publication date
IL272300B1 (en) 2025-08-01
EP4659806A2 (en) 2025-12-10
MX2024000348A (es) 2024-01-26
CN118593507A (zh) 2024-09-06
LT3661514T (lt) 2025-11-10
US20260007671A1 (en) 2026-01-08
MA49760B1 (fr) 2025-11-28
PL3661514T3 (pl) 2026-02-23
AU2024203872A1 (en) 2024-06-27
US20200054636A1 (en) 2020-02-20
IL272300A (en) 2020-03-31
CA3071948A1 (en) 2019-02-07
RS67534B1 (sr) 2026-01-30
MY208231A (en) 2025-04-25
EP3661514A1 (en) 2020-06-10
DK3661514T3 (da) 2025-12-15
HRP20251598T1 (hr) 2026-01-30
SI3661514T1 (sl) 2026-01-30
JP2025020292A (ja) 2025-02-12
SG11202000549TA (en) 2020-02-27
MA49760A (fr) 2020-06-10
US20240423981A1 (en) 2024-12-26
AU2018311974A1 (en) 2020-02-06
SMT202500413T1 (it) 2025-11-10
CN111182901A (zh) 2020-05-19
EP4659806A3 (en) 2026-02-18
FI3661514T3 (fi) 2025-12-12
IL272300B2 (en) 2025-12-01
JP2023065372A (ja) 2023-05-12
KR20250116181A (ko) 2025-07-31
RU2020109345A (ru) 2021-09-06
PT3661514T (pt) 2025-12-10
JP2020529996A (ja) 2020-10-15
US20220226324A1 (en) 2022-07-21
KR20200035973A (ko) 2020-04-06
WO2019028360A1 (en) 2019-02-07
MX2020001406A (es) 2020-03-09
SG10202112960QA (en) 2021-12-30
HUE073047T2 (hu) 2025-12-28
TWI907332B (zh) 2025-12-11
MX2024008096A (es) 2024-07-15
EP3661514B1 (en) 2025-09-17
TW201916882A (zh) 2019-05-01
UA130213C2 (uk) 2025-12-24
IL322175A (en) 2025-09-01
US20220313695A1 (en) 2022-10-06
US20250213565A1 (en) 2025-07-03
ES3055679T3 (en) 2026-02-13
UY37834A (es) 2019-02-28

Similar Documents

Publication Publication Date Title
US20250213565A1 (en) Treatment of hcm with pyrimidinedione compounds
CA3190060A1 (en) Methods of treatment with myosin modulator
TW202320763A (zh) 治療肥厚性心肌病之方法
KR20160095076A (ko) 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법
JP7620758B2 (ja) 肺動脈性肺高血圧症の治療方法
KR20250050043A (ko) 비폐쇄성 비대심근병증 치료 방법
JP2018135278A (ja) 循環器疾患及び／又はミトコンドリア病の改善用医薬
HK40026724A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
HK40026724B (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
HK40028703A (zh) 用於在肥厚型心肌病的治疗中使用的玛伐凯泰
US20250295639A1 (en) Methods for treating heart diseases
TW200418468A (en) Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events
Singh et al. Results: The results by analysis of varience revealed that wall thicknes opposite the site of infarction decreased from (mean±SD) 12.2±2.0 mm to 10.0±1.8 mm with coenzyme Q10 compared with 12.8±2.2 mm to 13.3+ 2.3
after Acute Converting Enzyme in Patients

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SEMIGRAN, MARC J.; LEE, JUNE H.; LAMBING, JOSEPH; GREEN, ERIC; EVANCHIK, MARC; CARLSON, TIMOTHY AND ZHANG, DAVID